In Brief: Medtronic InSync
This article was originally published in The Gray Sheet
Medtronic InSync: Bi-ventricular cardiac stimulator for treament of congestive heart failure is "moving into the clinical trial phase in the U.S.," company Chairman and CEO William George tells investors at a Feb. 3 session of the Piper Jaffray medical device conference in New York City. The device, which paces both sides of the heart through a proprietary transvenous lead system, "is progressing quickly through its initial 60-patient human clinical in Europe as well as in Canada," George notes, adding that "the greatest long-term opportunity for Medtronic in the pacing business is the treatment of congestive heart failure with biventricular cardiac stimulation" technology...
You may also be interested in...
Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.
With Warp Speed Decisions Already Made, Transitioning To Biden Admin Should Be No Trouble, Slaoui Says
As vaccines near availability, Moncef Slaoui says his full-time role at OWS may be ending. He has not met with the Biden Transition team, but notes that other Warp Speed officials have.
Strong top-line efficacy in pyruvate kinase deficiency patients who don’t receive regular transfusions looks approvable, analysts say, but Agios will await data in regularly transfused patients.